|
|
 Acceleron to Present at the BMO Capital Markets 9th Annual Focus on Healthcare ConferenceCAMBRIDGE, Mass. – July 30, 2009 –Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone and muscle, today announced that Steven Ertel, Vice President Corporate Development of Acceleron will provide a corporate presentation at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on Wednesday, August 5, 2009 at 4:30 PM (EDT). The conference will be held at the Millennium Broadway Hotel in New York City. About Acceleron Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of red blood cells, bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron’s scientific approach takes advantage of its unique insight into the regenerative powers of the TGF-beta superfamily of proteins. ACE-011 is currently being studied in two Phase 2 clinical trials in cancer patients. ACE-031 is currently being studied in a Phase 1 clinical trial in healthy volunteers. In addition, the company is advancing new product candidates that increase muscle mass, control angiogenesis, inhibit fat accumulation and increase hemoglobin. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron include Advanced Technology Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For more information, visit www.acceleronpharma.com. CONTACT: Acceleron Pharma: Mariesa Kemble (Media) |
| Home|Privacy Policy|Site Map|Website design by Garfield Group | © 2009 Acceleron Pharma. All rights reserved. |